Renoprotective effects of (+)-catechin in streptozotocin-induced diabetic rat model

Nutrition Research

Volumn 32, Issue 5, 2012, Pages 347-356

  Chennasamudram, Sudha P ^a   Kudugunti, Shashi ^a   Boreddy, Purushotham Reddy ^a   Moridani, Majid Y ^b   Vasylyeva, Tetyana L ^a  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b DEPARTMENT OF MEDICINE   (United States)

Author keywords

ACEi; Catechins; Diabetic nephropathy; Oxidative stress; Rat

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; CATECHIN; CREATININE; ENALAPRIL; ENDOTHELIN 1; FIBRONECTIN; GLUCOSE; MALONALDEHYDE; REACTIVE OXYGEN METABOLITE; THIOL;

ALBUMIN URINE LEVEL; ALBUMINURIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; BIOACCUMULATION; BODY WEIGHT; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; CREATININE URINE LEVEL; DIABETIC NEPHROPATHY; DRUG EFFECT; GLUCOSE BLOOD LEVEL; IN VITRO STUDY; IN VIVO STUDY; LIPID PEROXIDATION; MALE; MESANGIUM CELL; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RENAL PROTECTION; RENAL SYSTEM PARAMETERS; STREPTOZOCIN DIABETES; URINARY ALBUMIN EXCRETION; URINE LEVEL; URINE VOLUME;

ALANINE TRANSAMINASE; ALBUMINURIA; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIOXIDANTS; CAMELLIA SINENSIS; CATECHIN; CREATININE; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEPHROPATHIES; DISEASE MODELS, ANIMAL; ENALAPRIL; ENDOTHELIN-1; FIBRONECTINS; LIPID PEROXIDATION; MALE; OXIDATIVE STRESS; PHYTOTHERAPY; PLANT EXTRACTS; RATS; RATS, SPRAGUE-DAWLEY; SULFHYDRYL COMPOUNDS;

RATTUS;

EID: 84861679449     PISSN: 02715317     EISSN: 18790739     Source Type: Journal    
DOI: 10.1016/j.nutres.2012.03.015     Document Type: Article

References (49)

1. Fioretto P., Mauer M. Histopathology of diabetic nephropathy. Semin Nephrol 2007, 27(2):195-207.
2. Jefferson J., Shankland S., Pichler R. Proteinuria in diabetic kidney disease: a mechanistic viewpoint. Kidney Int 2008, 74:22-36.
3. Lee H.B., Yu M.-R., Yang Y., Jiang Z., Ha H. Reactive oxygen species-regulated signaling pathways in diabetic nephropathy. J Am Soc Nephrol 2003, 14:S241-S245.
4. Gorin Y., Block K., Hernandez J., Bhandari B., Wagner B., Barnes J.L., et al. Nox4 NAD(P)H oxidase mediates hypertrophy and fibronectin expression in the diabetic kidney. J Biol Chem 2005, 280:39616-39626.
5. Craven P.A., Melhem M.F., Phillips S.L., DeRubertis F.R. Overexpression of Cu2+/Zn2+ superoxide dismutase protects against early diabetic glomerular injury in transgenic mice. Diabetes 2001, 50:2114-2125.
6. Asaba K., Tojo A., Onozato M.L., Goto A., Quinn M.T., Fujita T., et al. Effects of NADPH oxidase inhibitor in diabetic nephropathy. Kidney Int 2005, 67:1890-1898.
7. Shotan A., Widerhorn J., Hurst A., Elkayam U. Risks of angiotensin-converting enzyme inhibition during pregnancy: experimental and clinical evidence, potential mechanisms, and recommendations for use. Am J Med 1994, 96:451-456.
8. Friedman J.M. ACE inhibitors and congenital anomalies. N Engl J Med 2006, 354:2498-2500.
9. Einhorn L.M., Zhan M., Hsu V.D., et al. The frequency of hyperkalemia and its significance in chronic kidney disease. Arch Intern Med 2009, 169:1156-1162.
10. Kurnik D., Vesterman-Landes J., Bialik M., Katzir I., Lomnicky Y., Halkin H., et al. Hyperkalemia and renal function during monotherapy and dual renin-angiotensin blockade in the community setting. Clin Ther 2011, 33:456-464.
11. Ferrándiz M.L., Alcaraz M.J. Anti-inflammatory activity and inhibition of arachidonic acid metabolism by flavonoids. Agents Actions 1991, 32:283-288.
12. Sabu M.C., Smitha K., Kuttan R. Anti-diabetic activity of green tea polyphenols and their role in reducing oxidative stress in experimental diabetes. J Ethnopharmacol 2002, 83:109-116.
13. Skrzydlewska E., Ostrowska J., Farbiszewski R., Michalak K. Protective effect of green tea against lipid peroxidation in the rat liver, blood serum and the brain. Phytomedicine 2002, 9:232-238.
14. Yokozawa T., Nakagawa T., Kitani K. Antioxidative activity of green tea polyphenol in cholesterol-fed rats. J Agric Food Chem 2002, 50:3549-3552.
15. Rahman I., Biswas S.K., Kirkham P.A. Regulation of inflammation and redox signaling by dietary polyphenols. Biochem Pharmacol 2006, 72:1439-1452.
16. Hollman P.C., Arts I.C. Flavonols, flavones and flavanols-nature, occurrence and dietary burden. J Sci Food Agric 2000, 80:1081-1093.
17. Rhee S.J., Kim M.J., Kwag O.G. Effects of green tea catechin on prostaglandin synthesis of renal glomerular and renal dysfunction in streptozotocin-induced diabetic rats. Asia Pacific J Clin Nutr 2002, 11:232-236.
18. Hase M., Babazono T., Karibe S., Kinae N., Iwamoto Y. Renoprotective effects of tea catechin in streptozotocin-induced diabetic rats. Int Urol Nephrol 2006, 38:693-699.
19. Renno W.M., Abdeen S., Alkhalaf M., Asfar S. Effect of green tea on kidney tubules of diabetic rats. Br J Nutr 2008, 100:652-659.
20. Bolzon A.D., Bianchi M.S. Genotoxicity of streptozotocin. Mutat Res 2002, 512:121-134.
21. Danda R.S., Habiba N.M., Rincon-Choles H., Bhandari B.K., Barnes J.L., Abboud H.E., et al. Kidney involvement in a nongenetic rat model of type 2 diabetes. Kidney Int 2005, 68:2562-2571.
22. Butler A.R. The Jaffe reaction. Identification of the coloured species. Clin Chim Acta 1975, 59:227-232.
23. Yamabe N., Yokozawa T., Oya T., Kim M. Therapeutic potential of (-)-epigallocatechin 3-O-gallate on renal damage in diabetic nephropathy model rats. J Pharmacol Exp Ther 2006, 319:228-236.
24. Lawrence J.M. Lipid peroxidation-DNA damage by malondialdehyde. Mutat Res 1999, 424:83-95.
25. Kudugunti S., Vad N., Ekogbo E., Moridani M. Efficacy of caffeic acid phenethyl ester (CAPE) in skin B16-F0 melanoma tumor bearing C57BL/6 mice. Invest New Drugs 2009, 1-11.
26. Vad N.M., Kudugunti S.K., Graber D., Bailey N., Kalkunte S., Moridani M.Y. Efficacy of acetaminophen in skin B16-F0 melanoma tumor-bearing C57BL/6 mice. Int J Oncol 2009, 35:193-204.
27. Wallin B., Rosengren B., Shertzer H.G., Camejo G. Lipoprotein oxidation and measurement of thiobarbituric acid reacting substances formation in a single microtiter plate: its use for evaluation of antioxidants. Anal Biochem 1993, 208:10-15.
28. Gergel D., Cederbaum A.I. Interaction of nitric oxide with 2-thio-5-nitrobenzoic acid: implications for the determination of free sulfhydryl groups by ellman's reagent. Arch Biochem Biophys 1997, 342:282-287.
29. Sedlak J., Lindsay R.H. Estimation of total, protein-bound, and nonprotein sulfhydryl groups in tissue with Ellman's reagent. Anal Biochem 1968, 25:192-205.
30. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976, 72:248-254.
31. Ribaldo P.D., Souza D.S., Biswas S.K., Block K., Lopes de Faria J.M., Lopes de Faria J.B. Green tea (Camellia sinensis) attenuates nephropathy by downregulating Nox4 NADPH oxidase in diabetic spontaneously hypertensive rats. J Nutr 2009, 139:96-100.
32. Tesch G.H., Allen T.J. Rodent models of streptozotocin-induced diabetic nephropathy. Nephrology 2007, 12:261-266.
33. Chen N., Bezzina R., Hinch E., et al. Green tea, black tea, and epigallocatechin modify body composition, improve glucose tolerance, and differentially alter metabolic gene expression in rats fed a high-fat diet. Nutr Res 2009, 29:784-793.
34. Firth J.D., Ratcliffe P.J., Raine A.E., Ledingham J.G. Endothelin: an important factor in acute renal failure?. Lancet 1988, 332:1179-1182.
35. Wong W.T., Wong S.L., Tian X.Y., Huang Y. Endothelial dysfunction: the common consequence in diabetes and hypertension. J Cardiovasc Pharmacol 2010, 55:300-307.
36. Lerman A., Zeiher A.M. Endothelial function. Circulation 2005, 111:363-368.
37. Yanagisawa M., Kurihara H., Kimura S., Tomobe Y., Kobayashi M., Mitsui Y., et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988, 332:411-415.
38. Kohan D.E. Endothelin, hypertension and chronic kidney disease: new insights. Curr Opin Nephrol Hypertens 2010, 19:134-139.
39. Hunley T.E., Kon V. Glomerular filtration: still sympathetic to endothelin's influence?. J Am Soc Nephrol 2009, 20:1427-1429.
40. Moreau P., d'Uscio L.V., Shaw S., Takase H., Barton M., Lüscher T.F. Angiotensin II increases tissue endothelin and induces vascular hypertrophy: reversal by ETA-receptor antagonist. Circulation 1997, 96(5):1593-1597.
41. Kalani M. The importance of endothelin-1 for microvascular dysfunction in diabetes. Vasc Health Risk Manag 2008, 4:1061-1068.
42. Jawa A., Nachimuthu S., Pendergrass M., Asnani S., Fonseca V. Impaired vascular reactivity in African-American patients with type 2 diabetes mellitus and microalbuminuria or proteinuria despite angiotensin-converting enzyme inhibitor therapy. J Clin Endocrinol Metab 2006, 91:31-35.
43. Rahman M., Pressel S., Davis B.R., Nwachuku C., Wright J.T., Whelton P.K., et al. Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart AttackTrial (ALLHAT). Arch Intern Med 2005, 165:936-946.
44. Koya D., Hayashi K., Kitada M., Kashiwagi A., Kikkawa R., Haneda M. Effects of antioxidants in diabetes-induced oxidative stress in the glomeruli of diabetic rats. J Am Soc Nephrol 2003, 14:S250-S253.
45. Li J.-M., Shah A.M. ROS generation by nonphagocytic NADPH oxidase: potential relevance in diabetic nephropathy. J Am Soc Nephrol 2003, 14:S221-S226.
46. Porter N.A. Mechanisms for the autoxidation of polyunsaturated lipids. Acc Chem Res 1986, 19:262-268.
47. Salah N., Miller N.J., Paganga G., Tijburg L., Bolwell G.P., Riceevans C. Polyphenolic flavanols as scavengers of aqueous phase radicals and as chain-breaking antioxidants. Arch Biochem Biophys 1995, 322:339-346.
48. Hill B.G., Ramana K.V., Cai J., Bhatnagar A., Srivastava S.K. Measurement and identification of S-glutathiolated proteins. Academic Press. Methods Enzymol 2010, 473:179-197.
49. Donovan J.L., Crespy V., Manach C., Morand C., Besson C., Scalbert A., et al. Catechin is metabolized by both the small intestine and liver of rats. J Nutr 2001, 131:1753-1757.